Trajectories and predictors of high-occurrence pain flares in ambulatory cancer patients on opioids
Open Access
- 4 January 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 8 (1)
Abstract
Pain flares have a substantive impact on the quality of life and well-being of patients with cancer. We identified longitudinal trajectories (clusters) of cancer pain flares in ambulatory patients and sociodemographic and clinical predictors of these trajectories. In a prospective cohort study using ecological momentary assessment (mEMA), we collected patient-reported daily pain flare ratings data over 5 months and identified predictors and correlates using validated measures. The mean age of the sample (N = 270) was 60.9 years (SD = 11.2), 64.8% were female, and 32.6% self-identified as African American. Four pain flare clusters were identified. The “high-occurrence” cluster (23% of patients) experienced 5.5 (SD = 5.47) daily flares, whereas low-moderate clusters (77%) reported 2.4 (SD = 2.74) daily flares (P < .000). Those in the high-occurrence cluster reported higher pain scores (P = .000), increased pain-related interference (P = .000), depressive symptoms (P = .023), lower quality of life (P = .001), and reduced pain self-efficacy (P = .006). Notably, 67.2% of those prescribed opioids as needed (PRN only) were in the high-occurrence pain flare cluster, compared with 27.9% with PRN and around-the-clock opioid prescriptions (P = .024). Individual predictors of high-occurrence pain flares were income below $30 000, unemployment, being African American, lower education level, Medicaid insurance, current opioid misuse (COMM), baseline inpatient hospital stay duration, and PRN-only opioid regimen. In the multiple predictor model, lower education level, unemployment, COMM score, extended inpatient duration, and PRN-only opioid regimen remained significant. In ambulatory patients with cancer, high occurrence of pain flares may be mitigated by attention to opioid prescription factors and addressing social determinants of health needs of underserved patients.Keywords
Funding Information
- National Institutes of Health
This publication has 62 references indexed in Scilit:
- Racial disparities in opioid prescription and pain management among breast cancer survivorsCancer Medicine, 2023
- Evaluating opioid analgesic prescribing limits: A narrative reviewPharmacoepidemiology and Drug Safety, 2022
- Prescription Opioids Dispensed to Patients with Cancer with Bone Metastasis: 2011–2017The Oncologist, 2021
- Changes in Opioid Prescribing Patterns Among Generalists and Oncologists for Medicare Part D Beneficiaries From 2013 to 2017JAMA Oncology, 2020
- Strategies to Identify Patient Risks of Prescription Opioid Addiction When Initiating Opioids for PainJAMA Network Open, 2019
- Bridging the Critical Divide in Pain Management Guidelines From the CDC, NCCN, and ASCO for Cancer SurvivorsJAMA Oncology, 2018
- CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016JAMA, 2016
- Symptom burden in cancer survivors 1 year after diagnosisCancer, 2011
- Validation and Utility of a Self-report Version of PRIME-MDThe PHQ Primary Care StudyJAMA, 1999
- Detecting AlcoholismJAMA, 1984